Oramed Pharmaceuticals Inc (ORMP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $161.33M
Last updated: Nov 17, 2026 at 11:05 AM ET
Oramed Pharmaceuticals Inc (ORMP) Financials: Revenue, Profit and Cash Flow
Oramed Pharmaceuticals reported revenue of $2.00M for the fiscal year ended Dec 31, 2025. That year, net income was $64.05M with a net margin of 3202.5%, operating cash flow was -$9.14M and free cash flow was -$11.08M. The quarter ended Sep 30, 2026 had net income of $18.41M.
Revenue and Margins
Over the 9 years to Dec 2025, revenue grew from $641.00K, a compound annual rate of 13.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $2.00M | N/A | 0.7% | -754.4% | 3202.5% |
| Dec 2024 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2023 | $1.34M | -50.4% | 100.0% | -1176.8% | 412.3% |
| Dec 2022 | $2.70M | 0.0% | 100.0% | -1502.0% | -1397.1% |
| Dec 2021 | $2.70M | -0.3% | 100.0% | -896.2% | -822.7% |
| Dec 2020 | $2.71M | +0.3% | 100.0% | -433.8% | -424.8% |
| Dec 2019 | $2.70M | +10.4% | 96.7% | -541.3% | -531.1% |
| Dec 2018 | $2.45M | -0.3% | 96.5% | -552.3% | -519.7% |
| Dec 2017 | $2.46M | +283.2% | 92.4% | -438.6% | -426.7% |
| Dec 2016 | $641.00K | N/A | 23.6% | -1561.6% | -1710.5% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income fell 62.0% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.00M | $0 | $1.34M | $2.70M | $2.70M | $2.71M | $2.70M | $2.45M | $2.46M | $641.00K |
| Cost of revenue | $1.99M | $193.00K | N/A | N/A | N/A | $90.00K | $90.00K | $86.00K | $187.00K | $490.00K |
| Gross profit | $13.00K | -$193.00K | $1.34M | $2.70M | $2.70M | $2.71M | $2.61M | $2.36M | $2.27M | $151.00K |
| Research and development | $6.38M | $6.32M | $8.97M | $27.64M | $20.99M | $10.23M | $13.52M | $11.98M | $10.28M | $7.71M |
| Operating income | -$15.09M | -$12.78M | -$15.77M | -$40.60M | -$24.22M | -$11.76M | -$14.63M | -$13.53M | -$10.77M | -$10.01M |
| Net income | $64.05M | -$19.06M | $5.53M | -$37.76M | -$22.24M | -$11.51M | -$14.36M | -$12.73M | -$10.48M | -$10.96M |
| EBITDA | $75.44M | N/A | $7.32M | -$40.54M | -$24.15M | -$11.75M | -$14.17M | -$13.49M | -$10.76M | -$9.99M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0 | $0 | $0 | $0 | $0 | $2.00M | $0 | $0 | $0 | $0 | $0 |
| Gross profit | N/A | $0 | -$30.00K | -$30.00K | -$31.00K | -$30.00K | $13.00K | -$31.00K | -$52.00K | -$54.00K | -$56.00K | -$53.00K |
| Operating income | -$4.10M | -$2.77M | -$3.66M | -$5.67M | -$2.43M | -$2.49M | -$4.50M | -$3.60M | -$3.09M | -$3.13M | -$2.96M | -$3.88M |
| Net income | $18.41M | $78.16M | $38.31M | $10.01M | $48.40M | $13.29M | -$7.64M | -$10.19M | -$19.62M | $9.21M | $1.54M | $13.34M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $285.00K by $45.66M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $230.86M | $155.28M | $220.55M | $161.64M | $128.00M | $44.63M | $34.66M | $47.40M | $38.71M | $42.83M |
| Current assets | $133.27M | $143.22M | $162.58M | $157.11M | $95.34M | $40.51M | $33.32M | $31.04M | $20.30M | $31.23M |
| Cash and equivalents | $45.95M | $54.42M | $9.05M | $40.46M | $77.25M | $19.30M | $3.33M | $5.00M | $3.97M | $3.91M |
| Total liabilities | $31.12M | $9.93M | $57.66M | $10.49M | $11.48M | $11.75M | $15.27M | $16.29M | $19.47M | $16.64M |
| Short-term debt | $285.00K | $216.00K | $51.28M | $247.00K | $130.00K | $44.00K | N/A | N/A | N/A | N/A |
| Shareholder equity | $199.74M | $146.26M | $163.82M | $151.81M | $115.77M | $32.88M | $19.39M | $31.11M | $19.24M | $26.19M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $400.92M | $369.64M | $268.85M | $230.86M | $220.49M | $161.68M | $147.54M | $155.28M | $165.08M | $184.22M | $203.65M | $220.55M |
| Total liabilities | $61.83M | $52.17M | $30.57M | $31.12M | $18.16M | $8.10M | $7.64M | $9.93M | $9.56M | $8.07M | $37.93M | $57.66M |
| Cash and equivalents | $28.93M | $15.24M | $13.20M | $45.95M | $52.18M | $15.80M | $74.52M | $54.42M | $42.10M | $84.75M | $18.58M | $9.05M |
| Shareholder equity | $339.09M | $317.47M | $238.28M | $199.74M | $203.28M | $154.53M | $140.81M | $146.26M | $156.44M | $177.06M | $166.64M | $163.82M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.14M | -$8.41M | -$10.29M | -$28.70M | -$21.18M | -$12.44M | -$12.94M | -$14.66M | -$5.83M | $4.66M |
| Capital expenditures | $1.93M | $18.00K | $254.00K | $496.00K | $375.00K | $82.00K | $15.00K | $5.00K | $7.00K | $9.00K |
| Free cash flow | -$11.08M | -$8.43M | -$10.55M | -$29.20M | -$21.56M | -$12.52M | -$12.95M | -$14.66M | -$5.84M | $4.65M |
| Dividends paid | $10.87M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | $5.44M | $105.82M | -$73.04M | $30.21M | -$22.26M | $4.63M | $11.26M | -$7.00M | $4.30M | -$16.01M |
| Financing cash flow | -$4.74M | -$52.04M | $51.98M | $11.56M | $101.39M | $23.79M | N/A | $22.65M | $1.59M | $12.04M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $426.00K | -$200.00K | -$2.92M | -$466.00K | -$1.63M | -$3.54M | -$3.52M | -$1.94M | -$7.07M | $2.07M | -$1.48M | -$1.34M |
| Capital expenditures | $4.00K | $2.00K | $5.00K | $202.00K | $289 | $4.03K | $3.00K | $11.02K | $4.98K | N/A | $2.00K | $2.00K |
| Free cash flow | $422.00K | -$202.00K | -$2.92M | -$668.00K | -$1.63M | -$3.54M | -$3.52M | -$1.95M | -$7.08M | N/A | -$1.48M | -$1.34M |
Frequently Asked Questions About ORMP
What is Oramed Pharmaceuticals' annual revenue?
Oramed Pharmaceuticals reported revenue of $2.00M for the fiscal year ended Dec 31, 2025.
Is Oramed Pharmaceuticals profitable?
Yes. Oramed Pharmaceuticals reported net income of $64.05M for the fiscal year ended Dec 31, 2025, with a net margin of 3202.5%.
How much free cash flow does ORMP generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$9.14M minus capital expenditures of $1.93M produced free cash flow of -$11.08M.
How much debt does Oramed Pharmaceuticals have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $285.00K and cash and equivalents of $45.95M.
What is ORMP's profit margin?
For the fiscal year ended Dec 31, 2025, Oramed Pharmaceuticals reported gross margin of 0.7%, operating margin of -754.4% and net margin of 3202.5%.
ORMP pages: Overview, Earnings, Forecast, Financials, Competitors